PDE3

Phosphodiesterase 3 (PDE3) is a dual-substrate cyclic nucleotide phosphodiesterase that hydrolyzes both cAMP and cGMP and serves as a key regulator of intracellular cyclic nucleotide signaling pathways controlling cardiovascular and metabolic function^[1][2]. PDE3-mediated regulation of cAMP signaling influences cardiac contractility, vascular smooth muscle tone, platelet activity, energy homeostasis, and insulin-responsive metabolic processes, thereby linking second-messenger turnover to diverse physiological responses^[1][2][3]. Mechanistically, PDE3 enzymes display high affinity for both cyclic nucleotides but preferentially hydrolyze cAMP, while cGMP acts as a competitive inhibitor of cAMP degradation, creating functional cAMP-cGMP signaling crosstalk^[1]. In disease-relevant systems, altered PDE3 signaling has been implicated in heart failure, ischemia-reperfusion injury, obesity-associated metabolic dysregulation, and abnormal insulin secretion, making PDE3 an important experimental target in cardiovascular and metabolic research^[2][3][4]. Compared with related isoforms, PDE3A is predominantly associated with cardiac myocytes, vascular tissues, platelets, and reproductive function, whereas PDE3B is enriched in adipocytes, hepatocytes, pancreatic β-cells, and other metabolic tissues where it mediates insulin-, IGF-1-, and leptin-responsive signaling pathways^[1][2][3]. This isoform-specific distribution underlies distinct biological functions and supports the use of selective genetic or pharmacological approaches to dissect cardiovascular versus metabolic mechanisms^[2][3][4]. For experimental applications, PDE3 inhibitors are widely used to enhance cAMP signaling and investigate cardiac contractility, platelet aggregation, vascular relaxation, and metabolic regulation in cellular and animal models^[1][2].